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Developed regions, including Japan, have become “aged societies,” and the number of adults with senile
dementias, such as Alzheimer's disease (AD), Parkinson's disease, and Huntington's disease, has also
increased in such regions. Neurotrophins (NTs) may play a role in the treatment of AD because endog-
enous neurotrophic factors (NFs) prevent neuronal death. However, peptidyl compounds have been
unable to cross the bloodebrain barrier in clinical studies. Thus, small molecules, which can mimic the
functions of NFs, might be promising alternatives for the treatment of neurodegenerative diseases.
Natural products, such as or nutraceuticals or those used in traditional medicine, can potentially be used
to develop new therapeutic agents against neurodegenerative diseases. In this review, we introduced the
neurotrophic activities of polyphenols honokiol and magnolol, which are the main constituents of
Magnolia obovata Thunb, and methanol extracts from Zingiber purpureum (BANGLE), which may have
potential therapeutic applications in various neurodegenerative disorders.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The percentage of older adults is increasing with the medical
advances that have prolonged the lifespan of individuals. The
extensively accepted standard indicates that numerous countries,
including Japan and Germany, have become “aged societies”
(Table 1). In Japan, the population ratio of people agedmore than 65
years is estimated to reach 29.1% by 2020 and further increase to
38.8% by 2050 (according to data fromWorld Population Prospects:
The 2010 Revision, Japan).
The number of adults with senile dementias, such as Alz-
heimer's disease (AD), Parkinson's disease (PD), and Huntington's
disease (HD), has increased owing to the advent of this rapidly
aging society. In Japan, the elderly population with dementia will
increase to 4,700,000 by 2025 unless current medical treatments
are not signiﬁcantly improved (Table 2). Dementia causes serious
health problems to the elderly and burdens the overall society.
Although AD is not a normal consequence of aging, the greatest risk.
acological Society.
Production and hosting by Elseviefactor for AD is aging. AD is the most prevalent dementia (ac-
counting for 50%e80% of dementias, according to the Alzheimer's
Association, www.alz.org) and some of its causes have recently
been discovered. However, we still lack effective preventative or
curative therapies.
The senile dementias (AD, PD, and HD), brain trauma, and
amyotrophic lateral sclerosis are neurodegenerative diseases that
are often associated with synaptic loss and neuronal death. In most
cases, neuronal injuries occur after self-degeneration, toxic insults,
or lack of nutrients (1). AD is characterized by neuronal loss, and
the overall treatment strategy for AD is to prevent neuronal death
or to produce new neuronal cells in order to replenish the cells in
the degenerated regions. Neurotrophins (NTs) are expected to play
a role in the treatment of AD because neuronal death is prevented
by endogenous neurotrophic factors (NFs), such as nerve growth
factor (NGF) and brain-derived neurotrophic factor (BDNF) (2).
Therapeutic applications of NFs by intracranial injections, trans-
plantation of cells secreting NFs, or gene therapy have shown
promising results in animal models of neuronal degeneration with
learning and memory impairments as well as in clinical trials with
AD patients. Thus, NFs are likely to be useful agents for ameliorating
neurodegeneration (3). However, NFs were unable to cross the
bloodebrain barrier in clinical studies and were easily metabolized.r B.V. All rights reserved.
Table 1
The increase of people over 65-years old in various countries.
Ratio of aged 65þ (%)
Year 2020 2030 2040 2050
World 9.4 11.7 14.3 16.2
More developed regions 19.0 22.4 24.5 25.7
Less developed regions 7.5 9.8 12.5 14.7
Japan 29.1 31.6 36.1 38.8
China 12.0 16.5 23.3 25.6
India 6.3 8.3 10.5 13.5
United States of America 16.2 19.9 20.9 21.2
United Kingdom 18.7 21.1 23.0 23.6
Germany 23.0 28.0 31.0 30.9
France 20.3 23.1 24.9 24.9
Note: data from “World Population Prospects: The 2010 Revision” by United Na-
tions.
More developed regions: Europe, Northern America, Australia/New Zealand and
Japan.
The data for China don not include Hong Kong and Macao, Special Administrative
Regions (SAR) of China.
Japan: “2010 Population Census” by the Ministry of Internal Affairs and Commu-
nications. Future population Population&Household Projection (medium-mortality
assumption) by the National Institute of Population and Social Security Research.
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properties. Therefore, small molecules, which can mimic the
functions of NFs, might be promising alternatives for the treatment
of neurodegenerative diseases (4). In vitro, NTs can also promote
process outgrowth and survival. Thus, rat cortical neurons were
cultured to investigate the small neurotrophic molecules in natural
products, which resulted in the discovery of several active com-
pounds (5). There are some reports on the elucidation of the
mechanisms of natural products, but the detailed mechanism is yet
unclear. The present review focuses the neurotrophic activity of
polyphenols, honokiol and magnolol, the main constituents of
Magnolia obovata Thunb, and methanol extracts from Zingiber
purpureum (BANGLE), which may have potential therapeutic ap-
plications in various neurodegenerative disorders.2. AD: pathology and therapeutics
2.1. Pathology of AD
AD is a progressive neurodegenerative disorder characterized by
accelerated neuronal cell death resulting to dementia. The hallmark
pathological features are extracellular amyloid plaques and intra-
neuronal ﬁbrillar structures. The latter includes neuroﬁbrillary
tangles (NFTs), neuropil threads, and dystrophic neuritis that
invade amyloid plaques. The extracellular deposition of proteolytic
fragments of amyloid precursor protein (APP) is termed amyloid b
(Ab), whereas the ﬁbrillar pathologies are composed of the
microtubule-associated protein, tau, assembled into polymeric ﬁl-
aments, forming amyloid plaques (6). APP is a large type-1 trans-
membrane multidomain protein that performs multiple cellular
activities. The most frequently expressed isoforms in the brain are
APP695, APP751, and APP770. Secretases (a, b, and g) catabolize APP,
forming non-amyloidal and/or amyloid-derived products (7). b-Table 2
Patients with dementia (x 10,000) and the increasing trend.
Year 2010 2015 2020 2025
Patients with dementia 280 345 410 470
% of people above 65 years old 9.5 10.2 11.3 12.8
Note: data from National Institute of Population and Social Security Research, “Ja-
pan's Future Estimated Population: 2006 median Estimate”.secretase, also known as beta-site amyloid precursor protein
cleaving enzyme 1 (BACE1), cleaves APP at Met 671 to produce
soluble amyloid precursor protein b (sAPPb) and a C-terminal 99
fragment. This is then cleaved by g-secretase at Val 711 and Ala 713,
resulting in the formation of APP intracellular domain (AICD), Ab40,
and Ab42 peptides (8). Ab ﬁbrils are formed by the aggregation of
these amyloid peptides. On the other hand, a-secretase cleaves APP
at Lys 687 to form the soluble amyloid precursor protein a (sAPPa)
and a C-terminal fragment of 83 amino acid residues. This fragment
is cleaved by g-secretase to produce non-amyloidogenic Ab17e42
[also known as protein 3 (p3)] and AICD. g-Secretase is a hetero-
tetrameric membrane-embedded aspartyl protease consisting of
four subunits: nicastrin, presenilin, anterior pharynx, and pre-
senilin enhancer 2 (9). When a- or b-secretase cannot cleave APP, it
is cleaved by g-secretase, forming the soluble amyloid precursor
protein g (sAPPg) and AICD (10). Some drugs that target APP pro-
cessing are complex and challenging to design because of the
multiple functional enzymes and substrates involved. Polyphenols
are potential activators of a-secretase and inhibitors of b- and g-
secretase, resulting in a reduction in amyloid ﬁbril deposition in the
brain (11).
In AD, the tau that is present in NFLs is aberrantly phosphory-
lated and often proteolytically truncated at its C terminus (12).
Cleavage of tau at Glu 391 by a yet-to-be-identiﬁed protease is one
such proteolytic event. Tau truncated at this site is observed in the
NFTs in brains of AD patients (12). Such post-translational modiﬁ-
cations are believed to impair the ability of tau to bind/stabilize
microtubules.
The AD brain exhibits evidence of oxygen radical-mediated
damage. However, the ability to directly implicate this mecha-
nism in AD has been a difﬁcult task because of the evanescent
nature of oxygen radicals and the use of non-speciﬁc analytical
approaches. Oxidative stress increases in the AD brain. The central
nervous system (CNS) is particularly vulnerable to oxidative dam-
age because it has a high energy requirement, high oxygen con-
sumption rate, and relative deﬁcit of antioxidant defense systems
compared with that of other organs (13).
Brain insulin/insulin-like growth factor (IGF) resistance and
deﬁciency are accompanied by impairments in glucose utilization
and disruption of energy metabolism, with attendant increases in
the mitochondrial dysfunction, oxidative stress, production of
reactive oxygen species (ROS), and DNA damage. All of these situ-
ations drive pro-apoptosis, pro-inﬂammatory, and pro-AbPP-Ab
cascades. Insulin stimulates the expression of glucose transporter
protein 4 (GLUT4) and protein trafﬁcking from the cytosol to the
plasma membrane to modulate glucose uptake and utilization. The
stimulation of GLUT4 with insulin is critical for regulating neuronal
metabolism and energy production, which are needed for memory
and cognition (14). Deﬁciencies in energy metabolism that are
caused by the inhibition of insulin/IGF signaling promote oxidative
stress, mitochondrial dysfunction, and pro-inﬂammatory cytokine
activation. Oxidative stress results in the generation and accumu-
lation of reactive oxygen and nitrogen species, which attack sub-
cellular organelles and cause chemical modiﬁcations of lipids,
proteins, DNA, and RNA. For example, adducts formed with mac-
romolecules can compromise the structural and functional integ-
rity of neurons due to the loss of membrane functions, disruption of
the cytoskeleton, dystrophy of synaptic terminals, deﬁcits in
neurotransmitter functions and plasticity, and perturbation of
signaling pathways for energy metabolism, homeostasis, and cell
survival. The expression and phosphorylation of tau are regulated
by insulin and IGF. In AD, brain insulin/IGF resistance reduces
signaling through phosphoinositol-3-kinase (PI3K) and Akt and
increases activation of glycogen synthase kinase 3b (GSK-3b) (15).
Overactivation of GSK-3b is partly responsible for the
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ﬁbril aggregation. The consequences include failure to generate
sufﬁcient quantities of normal soluble tau in relation to accumu-
lation of hyperphosphorylated insoluble ﬁbrillar tau and attendant
exacerbation of cytoskeletal collapse, neurite retraction, and syn-
aptic disconnection. Finally, intracellular AbPP-Ab directly in-
terferes with PI3K activation of Akt, impairing neuronal survival
and increasing GSK-3b activation and hyperphosphorylation of tau.
Consequently, hyperphosphorylated tau is prone to misfolding,
aggregation, and ubiquitination, prompting the formation of
dementia-associated paired-helical ﬁlament-containing neuronal
cytoskeletal lesions.
2.2. Therapeutics for AD
Alzheimer's disease is a process in which toxic Ab fragments are
generated (7) due to uncontrolled cleavage of APP by unknown
inducing factors. Alzheimer's disease is also characterized by am-
yloid ﬁbril and phosphorylated tau aggregates and tangles. At
present, there are two major problems with AD drug discovery.
(1) There is no available animal model that reﬂects all the
pathological events observed in the human AD brain.
(2) There is a lack of reliable biomarkers to detect and under-
stand the progression of AD.
Scientists are trying to develop drugs that can simultaneously
perform multiple tasks such as reducing inﬂammation, inhibiting
b-secretase, activating a-secretase, preventing Ab and tau aggre-
gation, and driving the disintegration of preformed ﬁbrils. How-
ever, no perfect drug or treatment of AD has been discovered so far,
and several drugs have failed in recent clinical trials.
2.2.1. Experimental models to screen neurotrophic compounds
The brain contains many types of neurons having different de-
grees of selectivity for NTs. Neurotrophic activity is experimentally
model-dependent; for example, septal cholinergic neurons in cul-
tures were extremely sensitive to NGF, whereas septal dopami-
nergic neurons were not (16). Small molecular weight neurotrophic
compounds also have different degrees of selectivity for neuronal
cells. Therefore, a compound may be signiﬁcantly sensitive to NTs
in one experimental model and extremely insensitive in another
model. Currently, several in vivo and in vitro screening models have
been designed to examine the different degrees of selectivity in
neurotrophic studies (Table 3).
A small molecule can mimic NTs by directly activating or
upregulating the NT receptors. Furthermore, a small molecule can
upregulate the expression of NTs, enhance the intracellular NT
signaling pathway, and/or inhibit the degradation of the trophic
signal. The physiological structure and function of the neurons are
maintained by the NTs when the neurons completely differentiate
into their neuronal phenotypes. Therefore, a lack of NTs in the bodyTable 3
Experimental models to screen neurotrophic compounds.
Cell lines PC12 cells (17), SH-SY5Y cells (18), P19 cells (19),
Neuro2A cells (20) et al.
Primary
cultured cells
cortical neurons (21), hippocampal neurons (21),
dorsal root ganglion neurons (22), spinal ventral horn
neurons (23),
medial septal neurons (24), retinal ganglion cells (25),
astrocytes (26) et al.
Tissue slices hippocampal slices (27) et al.
Whole animals senescence-accelerated mice 1 (SAMP1) (28), SAMP8 (29),
olfactory bulbectomized mice (30) et al.or withdrawal of NTs from the culture medium results in delete-
rious signals, which cause neuronal apoptosis.
2.2.2. Small molecular weight compounds with neurotrophic
activity
Compounds such as 1-{3-[2-(1-benzothiophen-5-yl)ethoxy]
propy-l}azetidin-3-ol maleate (T-817-MA), xaliproden, and DMXB-
A have neurotrophic activities and are in the clinical testing stage.
The ﬁrst of these has been developed as a therapeutic agent to treat
neurodegenerative disorders such as AD by modulating endoge-
nous antioxidative mechanisms. Phase II clinical trials are being




is a selective and potent 5-HT1A receptor agonist with low nano-
molar afﬁnity for the 5-HT1A receptors. Studies on xaliproden have
focused on the pro-neurotrophic properties of this compound in
cellular models, including rat pheochromocytoma PC12 cells, pri-
mary neuronal cells, and animal models of neurodegeneration (32).
DMXB-A {GTS-21; 3-[(2,4-dimethoxy)benzylidene]-anabaseine
dihydrochloride}is a derivative of the naturally occurring alkaloid,
anabaseine (33). It is a partial agonist of human a7 nicotinic re-
ceptors and, at higher concentrations, a weak antagonist of a4b2
receptors and serotonin 5-HT3 receptors (33). Approximately 40% of
the oral dose is absorbed within 1 h of administration (34). Me-
tabolites with hydroxyl substituents at positions 2 and 4 are more
efﬁcacious agonists when they are bound to the receptor, but the
extent of their production in the human brain in unknown (34).
DMXB-A improves memory in several animal models, and it nor-
malizes the inhibition of auditory responses in rodents with
signiﬁcantly less tachyphylaxis than that with nicotine. Mecamyl-
amine, an a4b2 antagonist, has a deleterious effect on conditioned
learning in young rabbits. The eyeblink classical conditioning
acquisition is improved in young rabbits administered with meca-
mylamine and DMXB-A (35). In aged rats, DMXB-A improves one-
way active avoidance and the performance in Lashley III maze
testing and 17-arm radial maze test (35). Passive avoidance deﬁcits
are normalized in rats and ischemia-induced hippocampal cell
death and impaired passive avoidance performance in gerbils are
prevented by treatment with DMXB-A (36). DMXB-A also improves
performance on the Morris water maze (35). Positive neuro-
cognitive effects, particularly on attention, were observed in
healthy volunteers administered with DMXB-A (37). All subjects
were evaluated for performance on a computerized test battery to
measure the effect of treatment on cognitive functions, including
changes in attention [simple reaction time (RT), choice RT, and digit
vigilance], numeric and spatial working memory, secondary
episodic recognition memory (word and picture recognition and
immediate and delayed word recall), and visual tracking. DMXB-A
signiﬁcantly improved performance on simple RT, choice RT, cor-
rect detection during digit vigilance, both word and picture
recognition memory, and both immediate and delayed word recall.
DMXB-A improved subject performance speed on numeric and
spatial working memory tasks. Improvement was generally
observed with a 25-mg dose, with further improvement at a 75-mg
dose, and an equivalent effect at a 150-mg dose (37).
2.2.3. Neurotrophic natural products
Natural products that are used in traditional medicine or as
nutraceuticals could potentially be used to develop new thera-
peutic agents against neurodegeneration. Illicium, the sole genus of
the family Illiciaceae, is distributed in the southern parts of China
(38). Majority of these plants are considered toxic; however, com-
pounds from these plants have demonstrated neuroactivity and are
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terize the plants according to their neurotrophic proﬁles, rat
pheochromocytoma PC12 cells (17), primary cultured rat cortical/
hippocampal neurons (21), and human neuroblastoma SH-SY5Y
cells (18) were used (Table 3). The rat PC12 cells are easy to cul-
ture and have been extensively used as a neuronal model because
they allow the screening of several compounds. Primary cultured
neurons bear majority of the in vivo neuronal properties, whereas
the SH-SY5Y cells contain human biochemical characteristics.
These three cellular models (PC12 cells, primary cultured neurons,
and SH-SY5Y cells) were utilized, and the biological characteristics
of the neurotrophic compounds discovered in the screening system
were classiﬁed. As a result, several neurotrophic compounds (i.e.,
alkaloids, terpenes, and phenols) were revealed. However, it is
unknownwhether the neurotrophic activities that occurred in vitro
would also transpire in vivo. Thus, it would be important to deter-
mine the amount of neurotrophic compounds that would be
required for systemic administration. Table 4 shows the com-
pounds that have been investigated in our laboratory.2.2.3.1. Polyphenolic compounds. Recent research is focusing on
natural products, such as the water extract of the leaves of Cae-
salpinia crista and Centella asiatica, Ginkgo biloba extract, and ex-
tracts prepared from themedicinal herb, Paeonia suffruticosa. These
products are alternatives for the treatment of AD (55). The water
extract of the leaves of C. crista prevents Ab aggregation from
monomers and disintegrates preformed Ab ﬁbrils. C. asiatica pre-
vents synuclein aggregation (56), G. biloba extract inhibits the for-
mation of oligomers (55), and extracts prepared from the medicinal
herb P. suffruticosa inhibit Ab ﬁbril formation and also destabilize
the preformed amyloid ﬁbrils (57). The anti-amyloidogenic prop-
erties observed are attributed to the polyphenolic compounds
present in these extracts. The chemical structure of polyphenols
includes two ormore phenol rings with hydroxyl groups in ortho orTable 4
Representative small-molecular weight natural compounds with neurotrophic ac-
tivity identiﬁed in our group.
Source Compound References




isonectandrin B, nectandrin B,
galgravin, aristolignin
(40)
Garcinia subelliptica garsubellin A (41)
Illicium anisatum illicinin A, 4-allyl-2-methoxy-6-
(2-methylbut-3-en-2-yl)phenol
(42)
Illicium fargesii isodunnianol (43)
Illicium jiadifengpi jiadifenoxolane A, jiadifenolide, (2R)-
hydroxy-norneomajucin
(44)
Illicium merrillianum merrilactone A (45)




Leonurus heterophyllus leonurusoleanolide A, B, C, D (47)
Magnolia ovobata honokiol, magnolol (28,29,48)
Mastigophora diclados mastigophorenes A, B, D (49)
Phellinus ribis ribisin A, B, C, D (50)
Phytolacca americana americanoic acid A methyl ester (51)
Piper retrofractum piperodione (5)
Plagiochila fruticosa plagiochilal B (27)
Ptychopetalum olaacoides ptychonal hemiaccetal, ptychonal (52)
Viburnum awabuki neovibsanin, neovibsanins A, B (53)








(30)para positions. The phenol rings are essential for redox reactions
(58). There is a direct positive correlation between the antioxidant
capacity and number of hydroxyl groups present in the poly-
phenols' structure. Thus, an increase in the amount of hydroxyl
groups in the polyphenol chemical structure is associated with an
increase in redox potential and antioxidant activity (59).
Polyphenols are powerful anti-amyloidogenic compounds
owing to their physicochemical features such as the presence of
aromatic rings, molecular planarity, capacity to form hydrogen
bonds, presence of an internal double bond, and molecular weights
below 500 g/mol. The molecular weight allows for potential inhi-
bition of APP pathways that, in turn, reduces amyloid load (60).
Several members of the disintegrin and metalloproteinase
(ADAM) family (ADAM9, 10, and 17) have been proposed to be
physiologically active a-secretases. It has been demonstrated that
ADAM10 has the highest a-secretase activity in vivo. Moreover, it
has been suggested that the upregulation of ADAM10 could be a
potential therapeutic target for the treatment of AD. ADAM10 has a
potential neuroprotective role because it promotes the non-
amyloidogenic pathway (61). This enzyme is activated by the
removal of the prodomain, which is probably promoted by the
action of proprotein convertases. Phlorotannins, curcumin, and
epigallocatechin-3-gallate (EGCG) have been shown to increase the
overexpression of sAPPa through activation of a-secretase, favoring
neuroprotection (62).
The amino acids, Asp 32 and Asp 228, and two water molecules
are essential for the catalytic activity of b-secretase, and all these
components are located in the catalytic binding site. One of these
water molecules participates in enzymatic proteolysis, whereas the
second water molecule is important for stabilizing a tetrahedral
intermediate that is essential for protein cleavage (63). Computa-
tional modeling studies have clariﬁed that Asp 32, not Asp 228, is
protonated (63). Proteolytic b-secretase activity is initiated through
a nucleophilic attack on the carbonyl group of the peptide bond by a
water molecule (63). The inhibition of b-secretase represents a
potential therapeutic target in AD treatment because it decreases
the Ab load. Isophthalamides have shown greater inhibitory effects
on b-secretase (63), and myricetin is a potential b-secretase in-
hibitor (64). The proposed mechanism is that the displacement of a
water molecule inhibits the polyphenol, and the water molecule
then participates in a hydrogen-bonding network with Asp 32 and
Asp 228, which is essential for b-secretase proteolytic activity (63).
Presenilin I (PS1) protein is a member of the aspartic protease
family, which is implicated in the regulation of intramembrane
proteolysis (9,65). Presenilin I has been identiﬁed as the catalytic
subunit of the g-secretase complex. This protein is composed of
nine transmembrane domains, and domains 6 and 7 form the
catalytic site. Mutations in PS1 have been linked to familial AD
(FAD). Therefore, PS1 is a potential target in the design of drugs
against AD (66). The catalytic activity of PS1 requires two opposing
aspartyl groups (Asp 257 and Asp 385) in the active site. One of
these aspartates is deprotonated and acts as a base, which activates
a water molecule present in the catalytic site. The other aspartate
donates a proton to the carbonyl group of the substrate (66).
Therefore, it is suggested that polyphenols that can occupy the
active site of g-secretase and displace the water molecule required
by the enzyme for catalysis, may disable the enzyme and reduce Ab
formation (66).
Aggregation of Ab42 is the central point of AD pathology.
Consequently, the inhibition of Ab42 aggregation is a key focus in
drug discovery. There are multiple steps involved in the biology of
Ab42 aggregation, i.e., monomers form oligomers, protoﬁbrils, and
mature ﬁbrils. Drug discovery efforts are focused on preventing the
formation of either oligomers or ﬁbrils. However, studies that
explore the binding of drugs to Ab42 and prevent ﬁbril formation
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peptide are hydrophobic residues. It has been suggested that the
hydrophobic core is essential for ﬁbrillogenesis (67). The ﬁbrilli-
zation of Ab, which begins with the formation of Ab oligomers that
are constituted by 24 monomers, is a multistep process (68). Am-
yloid ﬁbril formation depends on concentration of Ab42 peptide,
low pH, the time of incubation, and the length of the carboxyl chain
(69). The Ab structure is stabilized by hydrophobic forces, aromatic
stacking, and electrostatic interactions (70). The main physico-
chemical properties of molecules with the potential to inhibit
amyloidal ﬁbril formation might be due to the presence of aromatic
rings in their chemical structure and the ability to form non-
covalent interactions with amino acid residues of the Ab peptide
sequence (60). Moreover, the planarity of the inhibitor is essential
for increasing surface contact with the Ab peptides (71). Most
polyphenols have more than two aromatic rings, which are
essential for pep stacking interactions with the hydrophobic
amino acid residues of Ab (Tyr and Phe), and at least three hydroxyl
groups that form hydrogen bonds with the hydrophilic amino acid
residues of Ab (His6, Ser8, Tyr10, His14, and Lys16) (72). The
resonance structure of polyphenols provides enough planarity to
penetrate the Ab ﬁbril hydrophobic groove, thus disturbing the
ﬁbril structure (73).
Polyphenolic compounds, such as resveratrol, curcumin, and
myricetin, have demonstrated anti-Ab aggregation properties
(74,75). Furthermore, ﬂavanols possess more anti-amyloidogenic
activity than isoﬂavonoids because they contain more hydroxyl
groups that are able to form hydrogen bonds with Ab peptides.
Curcuminoids are more hydrophobic than ﬂavonoids. This physi-
cochemical property might enhance their afﬁnity for binding with
the hydrophobic core of the Ab ﬁbril, resulting in an increased anti-
amyloidal activity (76). Tannins are complex polyphenols that have
the highest number of hydroxyl groups of all the polyphenolic
compounds; therefore, they have the strongest anti-aggregation
activity (77). However, their large molecular weight reduces their
suitability as a therapeutic drug (78).
Our understanding of the bioavailability and health beneﬁts of
polyphenols remains unclear. However, it has been shown that











Fig. 1. Structures of honokiol and magnolol.2.2.3.2. Neurotrophic activity of honokiol and magnolol
2.2.3.2.1. Neurite outgrowth promotes activities in cortical neu-
rons. Honokiol andmagnolol are bioactive compounds found in the
stem bark of the M. obovata Thunb (Wakoboku) and Magnolia
ofﬁcinalis Rhed (Houpu) (80). Honokiol and magnolol are herbal
drugs (called “Kouboku”) used in China and Japan for the treatment
of digestive and nervous complaints.
Neurons were placed in cultures that contained honokiol or
magnolol. The neurons that were in honokiol-containing cultures
had extremely long neurites and more prominent, darker-stained
neuronal soma compared with those of the neurons in the con-
trol culture. In addition, one of the processes was much longer and
displayed more neurite branches. If bFGF were added to this cell
culture, the neurite extension could be signiﬁcantly enhanced. The
neurons that were in magnolol-containing cultures also had long
neurites. The length of neurites increased in the cultures that were
treated with honokiol or magnolol in a dose-dependent manner
and the neurites reached their maximum length at 10 mM.Magnolol
had a weaker effect on neurite extension compared with that of
honokiol. This difference in the trophic effects caused by honokiol
and magnolol presumably results from the different positions of an
arylearyl bond that is formed between two units of allylphenol
(Fig. 1) (81). These results are consistent with previous studies thathave shown that honokiol is more effective than magnolol at pro-
ducing various CNS-related effects (82).
2.2.3.2.2. Prevention of learning and memory impairment in
senescence-accelerated-prone mice (SAMP). Senescence-accelerated
mice (SAM) are selected by brotheresister mating of AKR/J mice
and are characterized by a rapid accumulation of senile features
and a shortened lifespan (1e1.5 years compared with that of 2e2.5
years in control animals) (83). SAM are composed of nine inbred
strains of senescence-accelerated-prone mice (SAMP), and three
strains of senescence-accelerated-resistant mice (SAMR), the latter
of which show normal aging. Neither SAMP1 nor SAMR1 mice are
behaviorally or morphologically different until they are 4 months
old. At that age, the SAMP1mice begin to rapidly accumulate senile
changes. These mice have decreases in orientation ability and
learning capacity and the appearance of age-speciﬁc morphological
changes such as lordokyphosis, hair loss, frequent corneal cataracts,
and mucosal inﬂammation (28). Among the various SAMP sub-
strains, SAMP8 mice exhibit early-onset impairment of learning
and memory (84). Recent studies have reported that aged SAMP8
mice had cholinergic neuron deﬁcits in the septal region of the
forebrain (85). These ﬁndings suggest that the SAMP8mouse might
be a useful animal model for investigating the cholinergic hy-
pothesis of human dementia in advanced aging and AD.
Magnolol (5 and 10 mg/kg) was orally administered once a day
for 14 days to 2- or 4-month-oldmice. Themicewere examined at 4
and 6 months of age. In the SAMP1 mice, the density of the neu-
roﬁbrils in the stratum radiatum of the CA1 region in the hippo-
campus decreased with age. This result was not observed in the
SAMR1mice.When 2-month-oldmicewere treatedwithmagnolol,
the decrease in neuroﬁbrils in the CA1 region was signiﬁcantly
prevented. However, magnolol administration at 4 months of age
did not result in a protective effect. These ﬁndings suggest that
magnolol must be administered before neuronal loss begins in or-
der to have a protective effect on the hippocampus (28).
Magnolol or honokiol was orally administered once a day for 14
days to 2-month-old SAMP8 mice. Passive avoidance tests and
object recognition tests were used to evaluate learning and mem-
ory at 4 and 6 months of age. Learning and memory in the SAMP8
mice were markedly impaired at 4 and 6 months of age. However,
this age-related learning and memory impairment was prevented
M. Akagi et al. / Journal of Pharmacological Sciences 127 (2015) 155e163160by the pretreatment with magnolol (10 mg/kg) or honokiol (1 mg/
kg). Immunohistochemical analysis of choline acetyltransferase
(ChAT) was used to evaluate the forebrain cholinergic neuron
densities in the medial septum and vertical limb of the diagonal
band. Signiﬁcant cholinergic deﬁcits were observed in 6-month-old
SAMP8 mice. However, this age-related cholinergic deﬁcit was
prevented by the pretreatment with magnolol (10 mg/kg) or hon-
okiol (1 mg/kg) (29).
2.2.3.2.3. Neurotrophic mechanisms of honokiol and magno-
lol. Fig. 2 illustrates the signal pathways of the NTs in neuronal cells
(86). Neurotransmitters, such as NGF, BDF, and NT-3, bind to the
extracellular domain of the tyrosine kinase receptors, TrkA, TrkB,
and TrkC, respectively, and activate tyrosine kinase in the intra-
cellular domain. The autophosphorylation of multiple tyrosine
residues within the intracellular segments produces several bind-
ing sites for intracellular signaling proteins. When the target signal
proteins bind to tyrosine kinase, they are phosphorylated to adopt
active forms and then activate downstream products (87). The NT-
activated signal molecules {Ca2þ, MAPK [Extracellular signal-
regulated kinases (ERK)], and Akt} in Fig. 2 are indispensable for
transferring intracellular signals to the nuclei.
The effects of honokiol and magnolol have been explained by
their effects on GABAA receptors (88). In primary cultured rat
cortical neurons and human SH-SY5Y cells, honokiol and magnolol
increased cytoplasmic free Ca2þwith a characteristic lag phase. The
increase in cytoplasmic free Ca2þ was independent of extracellular
Ca2þ, but dependent on phospholipase C (PLC) and inositol 1,4,5-
trisphosphate (IP3) receptor activation. These results suggest that
honokiol and magnolol increase cytoplasmic free Ca2þ through a
PLC-mediated pathway. Furthermore, the release of Ca2þ from
intracellular storesmainly contributes to an increase in cytoplasmic
free Ca2þ. Thus, honokiol and magnolol may be involved in the
activation mechanism associated with intracellular Ca2þ mobili-
zation (18). ERK1/2 and Akt might be related to the honokiol-
induced neurite outgrowth and intracellular Ca2þ mobilization.
This is suggested because the outgrowth in the cultured rat cortical
neurons was markedly reduced by PD98059, a mitogen-activated
protein kinase kinase (MAPKK, MAPK/ERK kinase MEK, directly
upstream from ERK1/2) inhibitor but not by LY294002, a PI3KFig. 2. Neurotrophic pathways of neurotrophins (NTs).(upstream from Akt) inhibitor. Honokiol also highly enhanced the
phosphorylation of ERK1/2 in a concentration-dependent manner.
The phosphorylation of ERK1/2 was enhanced by honokiol and
inhibited by KN93, PD98059, Ca2þ/calmodulin-dependent kinase II
(CAMK II) inhibitor, and MAPKK inhibitor. Products of the phos-
phoinositide speciﬁc PLC-derived IP3 and 1,2-diacylglycerol (DAG)
weremeasured after honokiol treatment (48). These results suggest
that the signal transduction from PLC, IP3, Ca2þ, and CAM II to
ERK1/2 is involved in the honokiol-induced neurite outgrowth.
The Akt pathway is a prominent regulator of NT-mediated sur-
vival responses in neurons. Activated Akt inhibits apoptosis
through multiple mechanisms and negatively regulates the phos-
phorylation and inactivation of the fork head transcription factors.
Akt activity was decreased in the forebrain of SAMP8 mice at 2
months of age compared with that of SAMR1 mice. However,
treatment with either magnolol or honokiol increased Akt phos-
phorylation in the forebrain of SAMP8 mice (29).
Regulation of oxidative stress may also explain the protective
effects of magnolol and honokiol in preventing age-related
impairment in SAMP8 mice. Magnolol and honokiol are known to
have antioxidant effects (89,90). The onset of increased lipid hy-
droperoxide in the brain coincides with the onset of cognitive
impairment in SAMP8 mice that are 2 months old. Thus, oxidative
stress may be important in the development of impaired learning
and memory (91).
2.2.3.3. BANGLE: evaluation of hippocampal neurogenesis in olfac-
tory bulbectomized (OBX) mice, an experimental depression and de-
mentia animal model. In the early stages of AD, the olfactory system
is signiﬁcantly impaired (92); it is particularly rich in acetylcholine
and other neurotransmitters and has decreased ChAT activity (93).
These results indicate that degeneration of cholinergic neurons
may occur in the olfactory system. Patients with AD have increased
numbers of senile plaques containing Ab and NFTs in the olfactory
bulbs (OBs) and the anterior olfactory nuclei (93). Previous studies
have shown that when the OBs are removed in animals (i.e., OBX
mice), the result is impaired learning and memory (94) with
increased exploratory behaviors (95). These results suggest that
OBX mice are an animal model for the investigation of experi-
mental depression and dementia. In mice, the intra-
cerebroventricular application of ﬁbroblast growth factor-2 (FGF-2)
ameliorates the reduction in hippocampal neurogenesis and re-
verses depressive behaviors induced by OB removal (96). The ol-
factory bulbectomization procedure was performed according to a
previously described method by Hozumi et al. (97). Two butenoid
dimmers, trans-3-(30,40-dimethoxyphenyl)-4-[(E)-300,400-dime-
thoxystyryl]cyclohex-1-ene (compound 1) and cis-3-(30,40-dime-
thoxyphenyl)-4-[(E)-300,400-dimethoxystyryl] cyclohex-1-ene
(compound 2) (Table 4) were isolated as neurotrophic molecules
from an Indonesian medicinal plant, Z. purpureum (Bangle). These
two compoundswere administered once a day on days 15e28 after.
Chronic treatment with compounds 1 and 2 signiﬁcantly increased
the number of BrdU/NeuN double-labeled cells (30). These results
indicate that compounds 1 and 2 have neurotrophic effects and
have the potential to modify depression and dementia.
2.2.3.4. Structure-activity relationships of natural pro-
ducts. Understanding the structureeactivity relationship of NFs is
important. However, using natural products to search for NF-like
molecules with similar structures is difﬁcult. Thus, these mole-
cules should be synthesized. Although this type of research has not
yet progressed, we have introduced it below.
The morphological effects of honokiol and its analogs on the
cultured rat cortical neurons were evaluated by the anti-MAP2
staining method. The 40-hydroxy group and the 50-allyl group
Fig. 3. Structures of illicinin A (A), and Aaed.
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outgrowth-promoting activity. However, the 30-allyl group was not
considered essential for neurite growth (Fig. 1) (98).
Illicinin A (A) and its derivatives (Fig. 3) were synthesized for the
structureeactivity relationship studies. Sequential Stille reactions
introduced a prenyl and allyl group to the benzene ring of A and its
derivatives. Thus, an allylphenyl moiety in the A molecule is
essential for its neurotrophic properties (42).
To further understand the structureeactivity relationship, the
neurotrophic properties of AaeAd were evaluated by measuring
the longest neurites among the rat cortical neurons cultured in the
presence of each analog. Among the screened compounds, Ac
decreased neurite outgrowth, whereas Aa, Ab, and Ad were com-
parable to A in terms of neurite outgrowth. These results indicate
that an allyl function in A is essential for preserving neurotrophic
activity. Among the active analogs, the activities of Aa and Ab,
which possess a 1,2-free diol group, slightly increased. This implies
that the presence of two vicinal oxy groups is important for neu-
rotrophic activity. However, the methylenedioxy forms of Aa and
Ab did not enhance their neurotrophic activities. In addition, the
presence and position of the prenyl group in A did not affect its
neurotrophic activity (42).3. Conclusions
Several small molecules, which can mimic the functions of NFs,
have been discovered in natural products. However, the neuro-
trophic activity has only been evaluated in vivo for a few com-
pounds. Magnolol, honokiol, and BANGLE extracts can supply the
amount of neurotrophic compounds that is required for adequate
systemic administration. Promising compounds with neurotrophic
activity may eventually be used for systemic administration. The
rapid discovery and production of a synthetic method for produc-
ing an effective compound in large quantities would be highly
desirable for the treatment of AD.Conﬂicts of interest
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